Breaking News, Collaborations & Alliances

Regulus, GSK Enter HCV Development Pact

Regulus Therapeutics has entered into a new collaboration with GlaxoSmithKline to develop and commercialize microRNA therapeutics targeting microRNA-122 in Hepatitis C Viral infection (HCV).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Regulus Therapeutics has entered into a new collaboration with GlaxoSmithKline to develop and commercialize microRNA therapeutics targeting microRNA-122 in Hepatitis C Viral infection (HCV). Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, as well as royalties on worldwide product sales. In exchange, GSK will have access to Regulus’ comprehensive intellectual property. Regulus’ paten...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters